MarketBeat sets USD 26.50 target for OrthoPediatrics stock

Published on 10/15/2026 at 19:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results come October 27, 2026. OrthoPediatrics stock costs EUR 20.20 on October 15, 2026, up 2.03 percent on Nasdaq.

Analyst target and reporting date

MarketBeat reported a seven-firm consensus target of USD 26.50 on October 15, 2026.
OrthoPediatrics is scheduled to report third-quarter results on October 27, 2026.
OrthoPediatrics stock costs EUR 20.20 at Lang & Schwarz on October 15, 2026 at 7:40 p.m. CEST, up 2.03 percent on Nasdaq versus the October 14, 2026 close.
The company had a market capitalization of USD 592.7 million and a price-to-earnings ratio of -13.54.

KIDS, US68752L1008, Illustration mit AI erstellt.

MarketBeat reported on October 15, 2026 that seven research firms covering OrthoPediatrics had a Moderate Buy consensus and an average 12-month target of USD 26.50. Against the USD 22.70 Nasdaq price, that target stood 16.74 percent higher. OrthoPediatrics stock was quoted at EUR 20.20 at Lang & Schwarz on October 15, 2026 at 7:40 p.m. CEST, while the Nasdaq price was up 2.03 percent versus the October 14, 2026 close.

October 27 results date

OrthoPediatrics is scheduled to release its third-quarter 2026 financial results after the market closes on October 27, 2026, according to the company's investor-relations page. The date gives investors the next defined checkpoint for revenue, earnings and the full-year outlook.

Stock sits below yearly high

The Nasdaq price stood at USD 22.70 on October 15, 2026 at 1:44 p.m. EDT, with a session high of USD 23.13 and a low of USD 22.30. Trading volume was 79,673 shares against an average volume of 211,366 shares. The stock's 52-week range was USD 14.42 to USD 26.74, leaving the latest price 15.11 percent below the high.

Valuation and business scale

OrthoPediatrics had a market capitalization of USD 592.7 million and a price-to-earnings ratio of -13.54 on October 15, 2026. The company markets more than 90 systems across trauma and deformity, scoliosis, and sports medicine, serving the United States and more than 75 other countries, according to its investor-relations page.

Comparison with peers

OrthoPediatrics (Nasdaq, USD): plus 2.03 percent, price-to-earnings ratio -13.54, market capitalization USD 592.7 million.

Globus Medical (NYSE, USD): plus 2.69 percent, price-to-earnings ratio 20.12, market capitalization USD 10.5 billion.

Stryker (NYSE, USD): plus 3.73 percent, price-to-earnings ratio 30.26, market capitalization USD 112.1 billion.

Price and investor calendar

The immediate market frame combines a 16.74 percent gap to the consensus target with a 15.11 percent distance from the 52-week high. The October 27 results date is the next scheduled event, while the negative price-to-earnings ratio reflects the company's reported loss profile.

OrthoPediatrics was trading at EUR 20.20 at Lang & Schwarz on October 15, 2026 at 7:40 p.m. CEST. The Nasdaq price was up 2.03 percent versus the October 14, 2026 close. The further course of trading is shown by the continuously updated real-time quote of OrthoPediatrics stock.